ADRB2 and arthritic joint disease: In present study, we sought to demonstrate that β2-AR signaling is dysregulated in chondrocytes both in vitro and in vivo just like in immune cells, and use of β2-AR agonist in the early phase of arthritis can prevent high grade inflammation and hence receptor desensitization in chondrocytes can be prevented.